Holen Sie sich die Stockscreener-App
0.6093
2.75%
0.0163
Handel nachbörslich:
.61
0.0007
+0.11%
Schlusskurs vom Vortag:
$0.593
Offen:
$0.61
24-Stunden-Volumen:
414.46K
Relative Volume:
0.36
Marktkapitalisierung:
$11.87M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.33M
KGV:
-0.0217
EPS:
-28.0369
Netto-Cashflow:
$-24.28M
1W Leistung:
+0.38%
1M Leistung:
-71.26%
6M Leistung:
-75.13%
1J Leistung:
-95.71%
1-Tages-Spanne:
$0.5646
$0.62
1-Wochen-Bereich:
$0.55
$0.66
52-Wochen-Spanne:
$0.1614
$15.75
Moleculin Biotech Inc Stock (MBRX) Company Profile
Firmenname
Moleculin Biotech Inc
Sektor
Branche
Telefon
713-300-5160
Adresse
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
0.6093 | 11.50M | 0 | -30.33M | -24.28M | -28.04 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-09 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-12 | Herabstufung | Maxim Group | Buy → Hold |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
Moleculin Biotech Inc Aktie (MBRX) Neueste Nachrichten
Moleculin (MBRX) Daily Snapshot: Climbs 0.49% to $0.61 for the Current Session; the Price Remains Bounded by the Supplied Support and Resistance at the CloseMcClellan Oscillator - vinanet.vn
Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Cuts Target Price to $2 - Moomoo
Moleculin Biotech Releases Q2 2026 Financial Results - AlphaStreet
Moleculin Biotech (NASDAQ: MBRX) seeks reverse split and plan changes at 2026 meeting - Stock Titan
Why Did MBRX Stock Climb 14% Today? - Stocktwits
Moleculin Biotech 2Q Research and Development Expenses $5.5M >MBRX - Moomoo
Moleculin Biotech expects cash position to fund operations into Q1 2027 - TradingView
Form 8K Moleculin Biotech Inc For: 14 August By Investing.com - Investing.com Canada
Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial - The Manila Times
Moleculin Biotech reports Q2 2026 loss of $7.6M, cash $7.3M; MIRACLE trial interim efficacy positive - TradingView
Moleculin Biotech Reports Second Quarter 2026 Financial - GlobeNewswire
Moleculin Biotech Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Moleculin Biotech (NASDAQ: MBRX) advances AML trial but warns on cash - Stock Titan
Moleculin Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
MBRX Q1 2026 Earnings: Wider-than-Expected Loss Reflects Clinical-Stage InvestmentLow Growth Earnings - vinanet.vn
Moleculin Biotech (MBRX): CVI and Heights disclose 1.86M-share, 9.9% ownership - Stock Titan
Q1 2025 Moleculin Biotech Inc Earnings Call Transcript - GuruFocus
Moleculin Biotech, Inc. Actuals & Estimates (NASDAQ:MBRX) - TradingView
Moleculin Biotech Inc expected to post a loss of $1.54 a shareEarnings Preview - TradingView
Moleculin Biotech (MBRX) stake capped at 4.99% under Intracoastal warrants - stocktitan.net
Moleculin Biotech, Inc. (MBRX) CFO buys 293,333 shares and 879,999 warrants - Stock Titan
Moleculin Biotech, Inc. (MBRX) CEO adds stock and 1.6M Series I warrants - Stock Titan
Moleculin Biotech (MBRX) CSO buys common stock and Series I Warrants - stocktitan.net
Price to sales forward of Moleculin Biotech, Inc. – LS:A41SET - TradingView
Moleculin reports promising preliminary phase II/III data for leukaemia drug Annamycin - Indian Pharma Post
Moleculin Biotech Raises $9.3 Million Equity; Signs Placement, Purchase and Lock-Up Agreements - TradingView
Form 424B5 Moleculin Biotech Inc For: 3 August By Investing.com - Investing.com South Africa
Moleculin Biotech Reports Positive Pivotal Phase 2/3 Trial Results for Annamycin in AML - The Indian Practitioner
Weekly Recap: MIRACLE Part A response rates and $0.75 unit offering - TradingView
Moleculin Biotech, Inc. SEC Filing (Aug 3, 2026) - Stock Titan
Moleculin Biotech (NASDAQ: MBRX) prices $9.3M stock and warrant offering - Stock Titan
Moleculin Biotech prices $9.3 million public offering By Investing.com - Investing.com Canada
Moleculin Announces Pricing of $9.3 Million Public Offering - marketscreener.com
Moleculin reports blinded remission data from leukemia trial By Investing.com - Investing.com Canada
Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients - The Manila Times
Moleculin Biotech (MBRX) Registration filing Summary - Quartr
IPO Databook: Moleculin Biotech (MBRX US)Jul 2026 - Smartkarma
Form S-1 Moleculin Biotech Inc For: 29 July By Investing.com - Investing.com Nigeria
Moleculin Biotech Files Registration Statement for Public Offering; Shares Fall - Moomoo
MBRX|Moleculin Biotech Inc|Price:2.190|Chg%:+0.070 - TradingKey
Moleculin Biotech Inc (MBRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Moleculin Biotech, Inc. Revenue Breakdown – NASDAQ:MBRX - TradingView
TradingKey - TradingKey
Enterprise value to EBIT forward of Moleculin Biotech, Inc. – NASDAQ:MBRX - TradingView
MBRX|Moleculin Biotech Inc|Price:2.160|Chg%:-0.030 - TradingKey
Moleculin Biotech Inc (MBRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Moleculin Biotech Inc (MBRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Moleculin Biotech Inc (MBRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Moleculin Biotech Inc (MBRX) Institutional Confidence - TradingKey
MBRX|Moleculin Biotech Inc|Price:2.150|Chg%:+0.030 - TradingKey
MBRX|Moleculin Biotech Inc|Price:2.160|Chg%:+0.040 - TradingKey
Finanzdaten der Moleculin Biotech Inc-Aktie (MBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):